Prosecution Insights
Last updated: November 20, 2026
Application No. 18/871,227

METHOD, DEVICE, AND PROGRAM FOR IDENTIFYING OR EVALUATING BILE CANALICULUS REGIONS

Non-Final OA §101§102
Filed
Dec 03, 2024
Priority
Jul 27, 2022 — JP 2022-119270 +1 more
Examiner
KNIGHT, TERESA E
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hamamatsu Photonics K.K.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
1y 5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
332 granted / 500 resolved
+6.4% vs TC avg
Strong +48% interview lift
Without
With
+47.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
36 currently pending
Career history
528
Total Applications
across all art units

Statute-Specific Performance

§101
7.3%
-32.7% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
12.9%
-27.1% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 500 resolved cases

Office Action

§101 §102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is responsive to the claim set dated Dec. 3, 2024, in which claim 1 was newly amended and claims 16-27 were newly added. Claims 1-4 and 16-27 are pending and examined below. Priority The present application is a 35 U.S.C. 371 national stage filing of the International Application No. PCT/JP2023/007107, filed Feb. 27, 2023 and claims foreign priority 35 U.S.C. 119(a)-(d) to JP2022-119270 filed on July 27, 2022. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Thus, the earliest possible priority for this application is July 27, 2022. Information Disclosure Statement The information disclosure statements filed Feb. 21,2025 and June 2, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS has been considered by the examiner. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-4 and 16-21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The claim(s) recite(s) a method of evaluating an observation object containing a hepatocyte, including an identification step (identifying the bile canaliculus region included in an observation object by using refractive index distribution) and an evaluation step (evaluating a bile canaliculus region on the basis of a parameter obtained from refractive index distribution data) or only an identification or evaluation step. The claims further recite a wherein step, which specifies that the bile canaliculus includes one parameter of an area of a cross section perpendicular to an axis of a tubular flow or cross section seen from a tomographic plane, a refractive index, the number of microvilli, or an average length of microvilli. This judicial exception is not integrated into a practical application because each of these steps appears to be mental. Even if the steps cannot be undertaken mentally, there is no recitation of any physical step; rather the outcome of something that might require a physical step is claimed. Neither the identification step nor the evaluation step results in any tangible, physical steps. A practitioner looking at a piece of paper or a computer screen could (or could not) be practicing the steps recited in this claim With respect to dependent claims 2 and 3, the additional limitation is directed to how the bile canaliuculus is identified, and thus these are still abstract steps. With respect to dependent claims 4, 16 and 17, these claims add limitations that refine the refractive index distribution data, which refines the identification step, but the claims still lack any tangible, physical manifestation that is not abstract. With respect to dependent claim 18, the additional limitation that the hepatocyte is a cluster of hepatocytes refines the scope of the identification step, but the claims still lack any tangible, physical manifestation that is not abstract. With respect to dependent claims 19 and 20, these claims do not add any additional limitations to either the identification step or the evaluation step; rather they specify that the method if only one of these. As such, neither of these claims results in any tangible, physical steps. With respect to claim 21, this claim does not add meaningful limitations to obviate the abstract idea exception – the claim requires both identification and evaluation and indicates that what is identified is also evaluated. With respect to claims 1-4 and 16-21, there are no active steps and the abstract idea is not integrated into a practical application With respect to claims 22 and 23, these claims do add limitations that require physical steps (cultivating a hepatocyte and added a drug to the hepatocyte, enabling the method to function as a drug screening evaluation). However, these physical steps are not enough to integrate these claims into a practical application because the only active steps recited by the claims amount to simply implementing the abstract idea (e.g. collecting the data that will be used for identification and evaluation). These are considered merely data gather steps required to use the abstract idea; they do not provide enough additional elements to amount to significantly more than the abstract idea – they are only insignificant extra-solution activity. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 19, 20 and 24-27 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Park Yong Keun (KR 10-1855366, cited in IDS filed on Feb. 21, 2025). Park Yong Keun teach methods for determining shapes of cells, including hepatocytes using the distribution data of refractive index of a sample containing cells. (paras. [0038]-[0040], [0043]-[0051], [0053], [0058], [0064]. As the method taught by Park Yong Keun must be able to distinguish cells from bile canaliculus (which are cell adjacent), the identification, or evaluation or both, apparatus and program are taught by the prior art such that the refractive index distribution data would enable bile canaliculus to be identified. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TERESA E KNIGHT whose telephone number is (571)272-2840. The examiner can normally be reached Monday-Friday 9-4. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached at 571-272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TERESA E KNIGHT/ Primary Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Dec 03, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §101, §102
Oct 27, 2026
Applicant Interview (Telephonic)
Oct 27, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790584
SUPPORTING BATH FOR THREE-DIMENSIONAL (3D) TISSUE CULTURE
4y 1m to grant Granted Nov 10, 2026
Patent 12788781
Cell Repair Protein Extract and Preparation Method therefor and Use thereof
2y 3m to grant Granted Nov 10, 2026
Patent 12781191
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
3y 11m to grant Granted Nov 03, 2026
Patent 12767926
ENGINEERED MITOCHONDRIA AND PREPARATION METHOD THEREOF
3y 0m to grant Granted Oct 20, 2026
Patent 12760279
EARLY MESENCHYMAL STEM CELLS WITH REDUCED AGING AND PRESERVED STEM CELL ABILITY, AND CULTURING METHOD THEREFOR
3y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+47.7%)
3y 5m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 500 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month